Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
MENLO PARK, Calif., Nov. 09, 2016 -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will present at the Stifel 2016 Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 11:00 a.m. ET (8:00 a.m. PT) on Wednesday, November 16, 2016, in New York City. A live audio webcast and replay of the presentation will be available in the Investors section of Dermira’s corporate website at www.dermira.com.
About Dermira
Dermira is a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases. Dermira’s portfolio includes three late-stage product candidates that target significant unmet needs and market opportunities: CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, in Phase 3 development for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); and DRM01, in Phase 2b development for the treatment of acne vulgaris. Dermira is headquartered in Menlo Park, California. For more information, please visit www.dermira.com.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com) and LinkedIn page (https://www.linkedin.com/company/dermira-inc-) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website and LinkedIn page in addition to following its SEC filings, press releases, public conference calls and webcasts.
Contacts: Media: Erica Jefferson Senior Director, Head of Corporate Communications 650-421-7216 [email protected] Investors: Andrew Guggenhime Chief Operating Officer and Chief Financial Officer 650.421.7200 [email protected] Robert H. Uhl Westwicke Partners Managing Director 858.356.5932 [email protected]
